Thymosin Alpha-1
Research OnlyA 28-amino acid immunomodulatory peptide approved in over 35 countries including China and Italy for hepatitis B/C, cancer adjuvant therapy, and immunodeficiency. Extensive human clinical trial data spanning decades with strong evidence for immune enhancement.
Ta1 · Thymalfasin · Zadaxin · TMSB1
28 human studies
- Preclinical
- 33%
- Human research
- 67%
Based on 42 cited sources
Numeric assessment unreviewed
A historical numeric score is recorded but has not passed a current, compound-specific assessment review. No numeric score is displayed.
This is a limitation of the numeric assessment, not a measured absence of benefit. It does not re-review the separately recorded catalogue classification or establish efficacy or safety.
Thymosin alpha-1 is a pleiotropic immunomodulator that enhances both innate and adaptive immunity through multiple pathways.
How It Works (Simplified)
Thymosin alpha-1 acts as an “immune training officer” that enhances multiple arms of the immune system:
Promotes T-cell maturation via TLR signaling on dendritic cells, helping immature T-cells develop into functional soldiers that recognize and attack pathogens and cancer.
Increases MHC class II expression and antigen presentation, making dendritic cells more effective at identifying threats and alerting the immune system.
Increases IL-2, IL-12, and IFN-gamma while modulating inflammatory cytokines - providing immune enhancement without hyperactivation.
Boosts natural killer cell proliferation and cytotoxic activity, enhancing the innate immune system’s rapid response to infected or cancerous cells.
Key Research: Romani L et al. (2004) showed that thymosin alpha-1 activates dendritic cells for Th1 immunity through Toll-like receptor and MyD88-dependent signaling. PMID:14982877
Important Limitations
- Not FDA-approved despite extensive clinical data and 35+ country approvals
- Most large trials are manufacturer-sponsored (SciClone Pharmaceuticals)
- Requires injection administration (subcutaneous, typically twice weekly)
- Effects depend on functional immune system capacity
Reported positives
- Immune system support reported during illness
- Used clinically in 35+ countries as Zadaxin
- Well-tolerated with minimal reported side effects
- Enhanced vaccine response noted in some reports
Reported negatives
- Expensive through compounding pharmacies
- Effects difficult to subjectively measure
- Not FDA-approved in the US despite global approval
- Autoimmune concerns with chronic immune stimulation
“Growing interest in immune optimization community. Global approval in 35+ countries adds credibility.”
Self-reported, unverified accounts — not clinical evidence and no substitute for the cited research. Anecdotes are prone to selection bias and placebo effects.
Based on clinical trials: Initial immune system modulation begins. T-cell maturation and dendritic cell activation observed. In hepatitis trials, immune markers begin to change within first 2 weeks.
PMID:21227010Immune enhancement effects become more pronounced. Clinical trials showed increased CD4+ T-cell counts and improved cytokine profiles. In hepatitis B trials, viral load reduction may begin.
PMID:21227010Studies show sustained immune enhancement with continued administration. Hepatitis B/C trials demonstrated viral response improvements over 24-52 weeks of treatment.
PMID:18078676Long-term studies in hepatitis and cancer adjuvant therapy show maintained immunomodulatory effects. In countries where approved, treatment courses of 6-12 months are common.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
LL-37
SynergisticBoth enhance innate immunity through complementary mechanisms - Ta1 via T-cell and dendritic cell activation, LL-37 via direct antimicrobial effects.
TB-500
CompatibleDespite both being thymosin-derived, they have distinct functions - Ta1 is immunomodulatory while TB-500 focuses on tissue repair via actin regulation.
BPC-157
CompatibleImmune enhancement from Ta1 may support tissue healing processes promoted by BPC-157, potentially beneficial in infection-prone wound scenarios.
Epithalon
CompatibleBoth developed by Russian researchers for different anti-aging targets - Ta1 for immune restoration, epithalon for telomere maintenance.
Selank
CompatibleBoth have immunomodulatory components - Ta1 as primary function, Selank as secondary effect from tuftsin backbone.
GHK-Cu
CompatibleTa1's immune support may enhance wound healing environments where GHK-Cu promotes collagen synthesis and tissue regeneration.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Use the source links in the research discussion above to inspect the referenced records.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Thymosin Alpha-1
Related Peptides
Alpha-Defensins
HNP-1 · HNP-2 · HNP-3 +5
A family of small cationic antimicrobial peptides (29-35 amino acids) that are key components of innate immunity in humans. Produced primarily by neutrophils (HNP-1 to 4) and Paneth cells (HD-5, HD-6), they exhibit broad-spectrum antimicrobial activity and immunomodulatory functions. Well-characterized biochemically with extensive research, though therapeutic development faces challenges.
KPV
Lys-Pro-Val · Lysine-Proline-Valine · alpha-MSH(11-13) +1
Lys-Pro-Val is the C-terminal tripeptide motif of alpha-MSH. KPV reduced inflammatory readouts in cell and mouse colitis models, including a PepT1 uptake study. Human drug exposure, pharmacokinetics, safety and clinical benefit remain unestablished.
Kristagen
EDG · Glu-Asp-Gly · Immune tripeptide
A synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.
Lactoferricin
LFcinB · Lactoferricin B · LfcinB +1
An antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. Shows broad-spectrum antimicrobial activity in laboratory studies. Research focuses on potential applications in infectious disease, food safety, and cancer. Primarily studied preclinically with very limited human clinical data. Not approved as a therapeutic by any regulatory agency.
LL-37
LL37 · Human cathelicidin antimicrobial peptide LL-37
LL-37 is the active human cathelicidin peptide. Three topical wound trials studied native LL-37, with mixed outcomes; an oral trial used engineered bacteria expressing LL-37. These results do not establish systemic benefit.
Murepavadin
POL7080 · RG7929
A first-in-class cyclic antimicrobial peptide targeting the LptD outer membrane protein of Pseudomonas aeruginosa. The first OMPTA (outer membrane protein targeting antibiotic) to reach clinical development. IV formulation discontinued due to nephrotoxicity; inhaled formulation continues Phase 3 development for cystic fibrosis and bronchiectasis patients.
Compared With
9 comparisonsConditions Studied
6 entries- Thymosin Alpha-1 for Hepatitis B Thymosin Alpha-1 is approved in multiple countries for chronic hepatitis B treatment. Clinical trials demonstrate enhanced respons…
- Thymosin Alpha-1 for Hepatitis C Thymosin Alpha-1 has been evaluated as adjuvant therapy for hepatitis C, particularly in combination with interferon and ribavirin…
- Thymosin Alpha-1 for Cancer Immunotherapy Thymosin Alpha-1 is used as a cancer immunotherapy adjuvant in multiple countries. Clinical trials have evaluated Ta1 as adjuvant…
- Thymosin Alpha-1 for Immunodeficiency Thymosin Alpha-1 addresses primary and secondary immunodeficiency through T-cell maturation enhancement. Studies in immunocompromi…
- Thymosin Alpha-1 for Viral Infections Beyond hepatitis, thymosin alpha-1 has been studied for various viral infections where cell-mediated immunity is important. Resear…
- Thymosin Alpha-1 for Aging Immune Function Immunosenescence (age-related immune decline) is a target for thymosin alpha-1. The thymus involutes with age leading to reduced T…